TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05456256: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Sponsor: Lantern Pharma Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$2,772,000

Rescue Site Savings

+$1,848,000

Unlock Full NCT05456256 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05456256 Rescue Dossier →